Gufic Biosciences Releases Q2 FY27 Earnings Call Transcript
Gufic Biosciences reported Q2 FY27 revenue of ₹288.4 crore, up from ₹230.4 crore in Q2 FY26, with PAT at ₹23.5 crore. The Indore plant received U.S. FDA pre-approval inspection and is expected to contribute to U.S. market entry by Q2/Q3 FY28. International expansion is progressing with new registrations and orders. The company targets 15-20% revenue growth and 22-25% EBITDA margins.
The announcement includes details on financial performance, significant regulatory milestones (US FDA inspection), international market penetration, and future growth drivers, all of which are material to investors.
The company reported growth in revenue and profit, with positive developments in international expansion and regulatory approvals for its Indore plant, indicating a positive outlook.
Gufic Biosciences Limited has released the written transcript of its Earnings Conference Call for the second quarter and first half of FY26-27, held on November 16, 2026. The call featured management including Mr. Pranav Choksi (CEO), Mr. Devkinandan Roonghta (CFO), and Ms. Ami Shah (Company Secretary).
The management discussed progress across various business segments. The Indore plant has received U.S. FDA pre-approval inspection, with the team addressing three observations. Compliance reports for Europe have been submitted, and audits from prospective U.S. and U.K. partners were hosted. New formats like the depot suite and spray-dried route for antifungal are nearing completion.
Internationally, the company secured registrations and first orders in Saudi Arabia and Chile, and received its first order in the U.K. and Germany. Italy was entered through a partner, and distribution was extended to five other European countries. Domestically, the hospital injectables segment saw the successful launch and widening use of AWABAC, growth in the anti-infective franchise, and increased contribution from own manufactured brands for Sparsh. The dual-chamber bag continues to gain acceptance. In women's health, Ferticare leads in recurrent implantation failure, and the Puregraf group deepened its presence in IVF chains. Cetrocare was introduced in a prefilled syringe format. The Zenova division is shifting towards prescription-led brands. Stunnox, the botulinum toxin brand, has completed five years and is the second-largest in its segment, with ongoing clinical studies and consensus recommendations for dosing in Indian patients. The healthcare division saw continued growth in the Sallaki range, with Gufican Oil being the fastest-growing brand.
Financially, for Q2 FY27, revenue from operations stood at ₹288.4 crore, compared to ₹230.4 crore in Q2 FY26. EBITDA increased to ₹49.7 crore from ₹37.9 crore, with a margin of 17.23% compared to 16.45%. Profit After Tax (PAT) rose to ₹23.5 crore from ₹14.9 crore. For the half-yearly results, revenue was ₹549.2 crore against ₹457.3 crore in the previous year, with PAT at ₹46 crore compared to ₹27 crore.
Management addressed concerns regarding a dip in EBITDA margin, attributing it to increased API import prices due to rupee devaluation and rising transportation costs, expecting normalization by Q4 FY27 or Q1 FY28. The Indore plant has achieved EBITDA breakeven and is expected to cover interest and depreciation by Q4 FY27. The company anticipates catering to the U.S. market by Q2 or Q3 FY28, and Europe/U.K. by September 2027 and February-March 2028 respectively, which is expected to drive revenue growth and margin expansion. Debt has increased due to higher working capital requirements, including an additional inventory of ₹40-50 crore due to geopolitical factors. The company aims for 15%-20% year-on-year revenue growth and targets an EBITDA margin of 22%-25% in the near future, with a 1% annual improvement.
What to do with a filing like this
Gufic Biosciences Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gufic Biosciences Limited. Read the original for the full detail.